[{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"National Cancer Institute | Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"Quadramet","moa":"Bone metastases","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ National Cancer Institute | Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ National Cancer Institute | Jazz Pharmaceuticals"}]
Find Clinical Drug Pipeline Developments & Deals for Quadramet
Details :
Sm-EDTMP is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteosarcoma.
Reset All
